Sequence Listing" in computer readable form as required by 37 C.F.R.§1.821(c) and §1.821(e). As required by 37 C.F.R. §1.821(f), Applicant's Attorney hereby states that the content of the "Second Substitute Sequence Listing" in paper form and the computer readable form of the further "Second Substitute Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Please amend the above-identified application as follows:

In the Abstract

Please replace the abstract now on file for the abstract submitted herewith, as follows. Amendments to the Abstract are indicated in the attached "Marked Up Version of Amendments" (page xii).:

B1

--The present invention relates to a human PAB II gene containing transcribed polymorphic GCG repeat, which comprises a sequence as set forth in SEQ ID NO:18, which includes introns and flanking genomic sequence. Allelic variants of GCG repeat of the human PAB II gene are associated with a disease related with protein accumulation in the nucleus, such as polyalanine accumulation, or with swallowing difficulties, such as oculopharyngeal muscular dystrophy. The present invention also relates to a method for the diagnosis of a disease associated with protein accumulation in the nucleus, which comprises the steps of: a) obtaining a nucleic acid sample of a patient; and b) determining allelic variants of GCG repeat of the PAB II gene, and wherein long allelic variants are indicative of a disease related with protein accumulation in the nucleus.--

In the Specification

Please insert the attached "Substitute Sequence Listing" (sheets 1/6 through 6/6), and comprising SEQ ID NOS: 1 through 21, into the above-referenced application.

In addition to the above changes, please amend the Specification as follows. Amendments to the Specification are indicated in the attached "Marked Up Version of Amendments" (pages i - ix).:

At page 1, line 14, through page 2, line 5, replace the paragraph with the following: